NCNA

NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update

NuCana Reports Positive Data and Future Milestones for NUC-7738

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;link type=&quot;text/css&quot; rel=&quot;stylesheet&quot; href=&quot;https://www.globenewswire.com/styles/gnw_nitf.css&quot;&gt;&lt;/li...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>NuCana plc reports favorable preliminary data for NUC-7738 in melanoma, particularly for patients resistant to PD-1 inhibitors. They expect to complete enrollment in the corresponding expansion study in mid-2026 and anticipate regulatory guidance from the FDA regarding registration pathways. With sufficient cash reserves until 2029, the company is well-positioned for its upcoming trials.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>NUC-7738 shows promising activity against PD-1 resistant melanoma.</li><li>Final data from the expansion study is expected in 2026.</li><li>NuCana has cash reserves to fund operations until 2029.</li><li>Enrollment in the Phase 2 study is expected to complete by mid-2026.</li><li>Regulatory guidance for NUC-7738&#039;s development is anticipated soon.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Pfizer (PFE)</strong>: Pembrolizumab (Keytruda) as a potential comparator in studies.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>The updates from NuCana reflect significant corporate developments concerning its clinical pipeline. With a focus on advancing new treatment options for cancer, especially resistant forms, the news is timely and potentially impactful for investor sentiment in the biotech sector.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>NUC-7738&#039;s ongoing studies could lead to bullish market sentiment.</li><li>Completion of enrollment and upcoming results may affect stock volatility.</li><li>FDA regulatory outcome could significantly impact valuation.</li><li>Market reaction expected on final data release scheduled for later in 2026.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>NUC-7738 demonstrates early clinical activity in PD-1 resistant melanoma patients.</li><li>Cash reserves stand at £24.3 million as of December 31, 2025.</li><li>Final data from the Phase 2 study expected later in 2026.</li><li>NuCana plans to seek FDA guidance for NUC-7738&#039;s registration strategy.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Invest in NCNA for potential upside driven by clinical data and FDA guidance within 12 months.</p>
  </section>
</section>


<article>
    <h2>NuCana Reports Strong Financial Results and Updates on Key Developments</h2>
    <p>EDINBURGH, United Kingdom, March 19, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: <a href="https://www.benzinga.com/quote/NCNA">NCNA</a>) has announced its financial results for the fourth quarter and year ended December 31, 2025, alongside a comprehensive update regarding its clinical development programs. These programs focus on advancing its two lead anti-cancer drugs, aimed at enhancing treatment outcomes for patients.</p>

    <h3>Clinical Advancements with NUC-7738</h3>
    <p>NuCana's Chief Executive Officer, Hugh S. Griffith, expressed enthusiasm regarding the company's prospects as it enters 2026. "We are excited to enter 2026 with significant momentum as we continue to advance the development of our ProTide pipeline with the aim to deliver significantly improved treatment outcomes for patients with cancer," he stated. The company showcased compelling data from the Phase 2 NuTide:701 study, which evaluated NUC-7738 in combination with pembrolizumab for treatment of PD-1 inhibitor-resistant metastatic melanoma. The findings revealed a favorable safety profile, clinical activity, and promising patient responses.</p>
    
    <h3>Upcoming Milestones for NUC-7738</h3>
    <p>Mr. Griffith highlighted the following anticipated milestones for 2026:</p>
    <ul>
        <li>Complete patient recruitment in the Phase 2 expansion study (NuTide:701) for NUC-7738 combined with pembrolizumab.</li>
        <li>Announce final data from the NuTide:701 expansion study.</li>
        <li>Obtain regulatory guidance from the U.S. Food and Drug Administration on a potential registrational pathway for NUC-7738 in melanoma.</li>
        <li>Advance evaluations of additional indications and combination strategies for NUC-7738.</li>
    </ul>
    
    <h2>Financial Highlights for Fourth Quarter and Year-End 2025</h2>
    <p>As of December 31, 2025, NuCana reported cash and cash equivalents of <strong>£24.3 million</strong>, reflecting a slight decrease from <strong>£25.2 million</strong> at the end of Q3 2025, but substantially higher than <strong>£6.7 million</strong> at the end of 2024. The funds raised through financing activities in 2025, which included:</p>
    <ul>
        <li><strong>£9.6 million</strong> in May 2025, comprising £5.2 million upfront and £4.4 million from warrants exercised.</li>
        <li><strong>£19.0 million</strong> raised through an at-the-market program in July 2025.</li>
    </ul>

    <p>These financial endeavors have solidified NuCana's cash runway, which is expected to extend into <strong>2029</strong>, enabling the execution of pivotal clinical and regulatory objectives.</p>
    
    <h3>Net Loss and Earnings Overview</h3>
    <p>NuCana experienced a net loss of <strong>£2.5 million</strong> for Q4 2025, compared to a net loss of <strong>£0.7 million</strong> for the same period in 2024. The net loss for the year was recorded at <strong>£29.4 million</strong>, a significant rise from <strong>£19.0 million</strong> in 2024. The results for 2025 included notable non-cash and non-recurring expenses, such as:</p>
    <ul>
        <li>Finance expenses of <strong>£12.6 million</strong> related to the fair value revaluation of warrants.</li>
        <li>Professional fees of <strong>£1.4 million</strong> associated with warrants.</li>
        <li>Share-based payment expenses of <strong>£10.0 million</strong>, up from <strong>£1.6 million</strong> in 2024.</li>
    </ul>

    <h3>About NuCana</h3>
    <p>NuCana is a clinical-stage biopharmaceutical company dedicated to transforming cancer therapies. By leveraging its proprietary ProTide technology, NuCana aims to develop superior and safer treatment options compared to traditional chemotherapy agents. The company's lead candidates, NUC-7738 and NUC-3373, are designed to address significant pharmacological limitations, thereby fostering improved therapeutic outcomes in solid and hematological tumors.</p>
</article>

NuCana plc reports favorable preliminary data for NUC-7738 in melanoma, particularly for patients resistant to PD-1 inhibitors. They expect to complete enrollment in the corresponding expansion study in mid-2026 and anticipate regulatory guidance from the FDA regarding registration pathways. With sufficient cash reserves until 2029, the company is well-positioned for its upcoming trials.

NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News